A smaller window to raise drug prices could lead drugmakers to look for other ways to generate growth, including M&A deals. (Photo: Shutterstock)
Washington wants drug prices to fall. Wall Street wants stock prices to rise. For some of the world's largest pharmaceutical companies, pleasing both sides could be a problem.
Last year, the industry promised restraint after President Donald Trump took aim at rising pharmaceutical costs. On Jan. 1, drugmakers returned to their annual practice of regular increases, boosting prices for dozens of treatments, from hot-selling arthritis therapies to painkillers at the center of the U.S. opioid epidemic.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
